Vivani Medical, Inc. (VANI) · Oct 30, 2026 · Other events

Vivani merger delayed as Cortigent awaits final approval

Closing delayed — October close slipped; final regulatory approval remains pending

Vivani’s merger update says Cortigent will not close in the expected October window without final regulatory approval, adding timing risk to the spinout.

Vivani is a clinical-stage biopharmaceutical company focused on long-acting drug implants, while Cortigent is its neurostimulation business being separated into a standalone public company. The merger was intended to let Vivani focus more narrowly on its drug-implant pipeline while moving Cortigent’s neurotechnology into a separately financed platform.

The transaction has slipped past its expected October close. Vivani had previously said the deal was expected to price and close in October, but the October 30 filing says final regulatory approval is still outstanding. 〔0〕

This is a timing setback, not a disclosed deal failure. The parties still expect closing shortly after approval, so the filing preserves the transaction’s basic structure but gives no firm closing date and confirms that the key remaining condition has not yet cleared. 〔1〕

The update is mildly worse than the standing expectation because October was the stated window. The direction of the event was partly known—the merger and its regulatory dependencies were already public—but the absence of approval by October 30 makes the timing less certain and delays the point at which Vivani can fully separate Cortigent.

Bottom line: The Cortigent separation remains alive, but the expected October completion has slipped into an open-ended wait for final regulatory approval. That matters mainly because it delays execution of Vivani’s planned business split rather than changing the deal’s strategic purpose.

What to watch next

Final regulatory approval and merger closing

Original filing on SEC EDGAR

Vivani merger delayed as Cortigent awaits final approval | VANI Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.